Jane Street’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.16M Buy
2,665,938
+941,634
+55% +$1.37M ﹤0.01% 3778
2025
Q4
$1.98M Buy
1,724,304
+1,267,774
+278% +$1.74M ﹤0.01% 4827
2025
Q3
$616K Sell
456,530
-348,137
-43% -$395K ﹤0.01% 7399
2025
Q2
$761K Buy
+804,667
New +$521K ﹤0.01% 6119
2025
Q1
Sell
-220,264
Closed -$163K 10123
2024
Q4
$163K Buy
220,264
+134,903
+158% +$163K ﹤0.01% 8537
2024
Q3
$134K Sell
85,361
-44,495
-34% -$79.2K ﹤0.01% 8863
2024
Q2
$218K Sell
129,856
-151,732
-54% -$272K ﹤0.01% 8261
2024
Q1
$676K Buy
281,588
+9,221
+3% +$19.8K ﹤0.01% 6135
2023
Q4
$417K Buy
272,367
+190,437
+232% +$226K ﹤0.01% 7080
2023
Q3
$89.3K Buy
81,930
+61,382
+299% +$108K ﹤0.01% 7999
2023
Q2
$47.1K Sell
20,548
-22,975
-53% -$61K ﹤0.01% 8223
2023
Q1
$106K Buy
43,523
+26,192
+151% +$60K ﹤0.01% 8199
2022
Q4
$33.1K Sell
17,331
-17,210
-50% -$36.6K ﹤0.01% 8476
2022
Q3
$83K Buy
+34,541
New +$95.6K ﹤0.01% 8739
2022
Q2
Sell
-19,723
Closed -$41K 10384
2022
Q1
$41K Sell
19,723
-18,744
-49% -$52K ﹤0.01% 9752
2021
Q4
$152K Sell
38,467
-1,253
-3% -$6.09K ﹤0.01% 8997
2021
Q3
$191K Buy
39,720
+24,509
+161% +$101K ﹤0.01% 8885
2021
Q2
$70K Sell
15,211
-7,465
-33% -$36K ﹤0.01% 9405
2021
Q1
$133K Buy
+22,676
New +$157K ﹤0.01% 8517
2020
Q4
Sell
-12,011
Closed -$17K 7843
2020
Q3
$17K Sell
12,011
-6,136
-34% -$10.9K ﹤0.01% 7038
2020
Q2
$36K Buy
+18,147
New +$35.6K ﹤0.01% 6909
2020
Q1
Sell
-13,991
Closed -$58K 5708
2019
Q4
$58K Sell
13,991
-47,175
-77% -$182K ﹤0.01% 4896
2019
Q3
$184K Buy
+61,166
New +$189K ﹤0.01% 4672
2014
Q1
Sell
-6,409
Closed -$81K 2906
2013
Q4
$81K Buy
6,409
+2,810
+78% +$44.7K ﹤0.01% 2208
2013
Q3
$60K Buy
+3,599
New +$60.4K ﹤0.01% 2591

Other funds holding LXRX

Jane Street's LXRX Position: Q1 2026 in Review

Jane Street increased its Lexicon Pharmaceuticals (LXRX) stake by 55% in Q1 2026, buying an estimated $1.37M and bringing the position to 2,665,938 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3778.

Jane Street first reported a position in LXRX in Q3 2013 and has held it in 25 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Jane Street held 2,665,938 shares of Lexicon Pharmaceuticals worth $4.16M as of Q1 2026.
  • Jane Street bought 941,634 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $1.37M.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3778 holding.
  • Jane Street first reported a position in Lexicon Pharmaceuticals in Q3 2013 and has held it in 25 quarters since.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.